Pharmaceutical Technology
MAY 22, 2024
When new medicines hit the market, sharing educational content with physicians, pharmacists, and patients is vital for ensuring safe and appropriate use.
Bio Pharma Dive
MAY 22, 2024
The deal, only Biogen’s third since the start of 2018, is a sign the company is open to branching out beyond the neurological drugs that have long been its focus.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 22, 2024
As the nitrosamine scandal continues, we explore the advancements in parenteral packaging materials that are reducing the risk of this contaminant in modern injectables.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 22, 2024
Climate change is making the symptoms of certain brain conditions worse, our new review has found. Conditions that can worsen as temperature and humidity rise include stroke, migraines, meningitis, epilepsy, multiple sclerosis, schizophrenia, Alzheimer’s disease and Parkinson’s.
Bio Pharma Dive
MAY 22, 2024
AstraZeneca has an exclusive chance to buy the startup, which is developing a muscle-protecting weight loss medicine, within the next two years.
Rethinking Clinical Trials
MAY 22, 2024
Dr. Doug Zatzick In a secondary analysis of data from the TSOS study pooled with data from 2 other comparative effectiveness trials, baseline patient clinical and demographic characteristics were associated with persistent symptoms of posttraumatic stress disorder (PTSD) symptoms and diminished treatment response. The report was published online ahead of print in Psychiatry.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
MAY 22, 2024
The Central Drugs Standard Control Organisation (CDSCO) has requested stakeholders to take appropriate action for timely reporting of adverse events related to medical devices to the Materiovigilance Programme of India (MvPI), in the backdrop of shifting the segment to licensing regime.
Bio Pharma Dive
MAY 22, 2024
Today’s rundown also includes news of an expanded partnership for Boehringer Ingelheim and updates to emerging medicines from GSK and Bristol Myers.
Pharmaceutical Technology
MAY 22, 2024
Genmab has concluded the acquisition of ProfoundBio, a clinical-stage biotechnology company, in an all-cash transaction valued at $1.8bn.
Bio Pharma Dive
MAY 22, 2024
Direct-to-consumer platforms can offer consumers an online path to sourcing popular medications, but some therapeutic areas may be better suited for the business model.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
MAY 22, 2024
Discover the key factors and latest advancements in pharmaceutical clean room manufacturing, flooring, and design to ensure full regulatory compliance.
BioSpace
MAY 22, 2024
Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron Therapeutics to develop novel therapies for oncology, neuroscience and inflammation.
Pharmaceutical Technology
MAY 22, 2024
Sanofi has entered a collaboration with Formation Bio and OpenAI aimed at harnessing AI to expedite drug development.
BioSpace
MAY 22, 2024
Amid its ongoing efforts to trim $4 billion in spending in 2024, Pfizer in an SEC filing on Wednesday said it is looking to save an additional $1.5 billion over the next several years.
Pharmaceutical Technology
MAY 22, 2024
Alvotech has entered into a collaboration with Dr. Reddy's Laboratories for the commercialisation of AVT03 in the US, Europe and the UK.
Fierce Pharma
MAY 22, 2024
Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. | Pfizer has made frequent headlines in recent months as it moves forward with a campaign to save $4 billion in annual costs by the end of this year. Now, the company has unveiled another savings drive that will run longer.
Pharmaceutical Technology
MAY 22, 2024
Evotec will close an Austrian facility as it shuts down its gene therapy business Evotec GT, a move which will affect 40 employees.
pharmaphorum
MAY 22, 2024
The debate rages on as NICE considers a 'clinically distinct disease' classification. Learn how this decision could reshape the STA process and patient treatment options.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
MAY 22, 2024
AltruBio has secured $225m in an oversubscribed Series B financing round to propel the clinical development of its ICE programme.
BioSpace
MAY 22, 2024
In advance of Friday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting, the FDA has raised concerns about hypoglycemia linked to Novo Nordisk’s insulin icodec, according to a briefing document.
Pharmaceutical Technology
MAY 22, 2024
AstraZeneca has the option to acquire SixPeaks in the next two years if the latter’s bispecific antibody proves successful.
pharmaphorum
MAY 22, 2024
A think tank set up by former UK Prime Minister Tony Blair has called for the formation of a public-private trust that could oversee the sharing of anonymised patient data with trusted researchers.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
MAY 22, 2024
Download our list of leading pharmaceutical process automation technologies to make an informed purchasing decision.
Fierce Pharma
MAY 22, 2024
Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on m | Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia.
Pharmaceutical Technology
MAY 22, 2024
Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.
pharmaphorum
MAY 22, 2024
GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Fierce Pharma
MAY 22, 2024
The more than 53,000 women in the U.S. | The more than 53,000 women in the U.S. who have filed injury lawsuits against Johnson & Johnson have added ammunition for their claims as new research indicates there is an association between long-term use of talcum-based powders and an increased risk of developing ovarian cancer.
BioSpace
MAY 22, 2024
BioSpace's Lori Ellis discusses the risks and challenges of cell and gene therapy combination products with DIA speakers James Wabby, AbbVie and Rob Schulz, Suttons Creek, Inc.
pharmaphorum
MAY 22, 2024
Lawmakers across the political divide have accused the pharma industry of abusing the patent system to keep the prices of their products as high as possible.
BioSpace
MAY 22, 2024
Orna Therapeutics announced Thursday it is acquiring ReNAgade Therapeutics, which launched in May 2023 with $300 million in Series A financing and is on BioSpace’s NextGen Class of 2024 startups to watch this year.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Expert insights. Personalized for you.
130 
Let's personalize your content